Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus

Lotan, Itay; Hellman, Mark A.; Steiner, Israel

doi:10.1111/ane.12394

Cited by 20 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Peripheral neuropathy in SEA is associated with multiple possible causes, such as metabolic disease (particularly diabetes mellitus), infections (human immunodeficiency virus [HIV] and hepatitis B or C virus), chronic inflammatory demyelinating polyneuropathy 2 , drug‐induced toxicity (cancer chemotherapy, antiretrovirals and antituberculous drugs) and vitamin deficiencies (vitamin B 1 , B 6 , B 12 , D) 3 . The causes of PN in these countries might also differ from rural to urban areas; for example, in the Philippines and India, workers in the agricultural sector are exposed to organophosphorus pesticides, which can lead to PN 4 .…”

Section: Peripheral Neuropathy In Seamentioning

confidence: 99%

Diagnosing peripheral neuropathy in South‐East Asia: A focus on diabetic neuropathy

Malik

Andag-Silva

Dejthevaporn

et al. 2020

J of Diabetes Invest

View full text Add to dashboard Cite

Burning and stabbing pain in the feet and lower limbs can have a significant impact on the activities of daily living, including walking, climbing stairs and sleeping. Peripheral neuropathy in particular is often misdiagnosed or underdiagnosed because of a lack of awareness amongst both patients and physicians. Furthermore, crude screening tools, such as the 10‐g monofilament, only detect advanced neuropathy and a normal test will lead to false reassurance of those with small fiber mediated painful neuropathy. The underestimation of peripheral neuropathy is highly prevalent in the South‐East Asia region due to a lack of consensus guidance on routine screening and diagnostic pathways. Although neuropathy as a result of diabetes is the most common cause in the region, other causes due to infections (human immunodeficiency virus, hepatitis B or C virus), chronic inflammatory demyelinating polyneuropathy, drug‐induced neuropathy (cancer chemotherapy, antiretrovirals and antituberculous drugs) and vitamin deficiencies (vitamin B1, B6, B12, D) should be actively excluded.

show abstract

Section: Peripheral Neuropathy In Seamentioning

confidence: 99%

Diagnosing peripheral neuropathy in South‐East Asia: A focus on diabetic neuropathy

Malik

Andag-Silva

Dejthevaporn

et al. 2020

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Although not yet validated in large populations, a screening tool has been proposed wherein clinicians could use a combination of clinical, electrophysiological, and laboratory parameters to more accurately identify CIDP versus DPN in patients with DM (Lotan, Hellman, & Steiner, 2015). Certain parameters supportive of CIDP and not seen in DPN were given a positive (+) value (eg, progressive/relapsing motor weakness of 2–6 months and distal CMAP duration of ≥9 ms in ≥1 nerve and ≥1 other demyelinating parameter in ≥1 other nerve).…”

Section: Distinguishing Cidp With Concomitant Diabetes From Dpnmentioning

confidence: 99%

“…Although validated in a small number of patients (N = 57), this tool correlates well with both AAN and EFNS criteria for CIDP (AAN, 1991; Van den Bergh & Pieret, 2004). Further studies with larger populations correlating with EFNS/PNS diagnostic criteria and, importantly, response to therapy, are needed (Lotan et al, 2015). …”

Section: Distinguishing Cidp With Concomitant Diabetes From Dpnmentioning

confidence: 99%

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy

Bril

Blanchette

Noone

et al. 2016

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Purpose We reviewed the literature on chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetes mellitus (DM) and explored real-world data on the prevalence and treatment of CIDP within DM. Methods: A literature search of Scopus was performed for the terms chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy, CIDP, and prevalence, incidence, epidemiology, or diabetes; peripheral neuropathy and prevalence or diabetes. We also searched through the reference lists of the resulting publications for additional findings that may have been missed. Additional publications on guidelines for the diagnosis of CIDP and diabetic neuropathy were also included. A descriptive analysis of the 2009–2013 PharMetrics Plus™ Database was performed to estimate the prevalence and treatment of CIDP within the DM population. Results There is an increasing body of literature suggesting that the prevalence of CIDP tends to be higher in diabetic patients, especially in those of older age. Our real-world data seem to support published findings from the literature. For the total cohort (N = 101,321,694), the percent prevalence of CIDP (n = 8,173) was 0.008%; DM (n = 4,026,740) was 4%. The percent prevalence of CIDP without DM (n = 5,986) was 0.006%; CIDP with DM (n = 2,187) was 9-fold higher at 0.054%. For patients >50 years old, there was a significantly higher percentage of CIDP with DM than CIDP without DM. Approximately 50% of CIDP patients were treated with IVIg, 23%–24% with steroids, 1%–2% with PE, and 20%–23% received no treatment. Conclusions In addition to the growing evidence of higher prevalence of CIDP in DM, our findings reinforce the need for heightened awareness of the association of CIDP and DM.

show abstract

“…1 The electrophysiological evaluation is essential for the diagnosis of CIDP. 2,3 Typical features comprise slow motor nerve conduction velocities (MCV), prolonged distal motor latencies (DML) and F-wave latencies, increased duration of the compound muscle action potentials (CMAPs), and low CMAP amplitudes. [4][5][6] In CIDP, reduced CMAP amplitudes are related to the degree of muscle weakness.…”

Section: Introductionmentioning

confidence: 99%

The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy

et al. 2016

View full text Add to dashboard Cite

show abstract

Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus

Abstract: These results show that this diagnostic tool is able to identify patients with diabetes with overlapping CIDP.

Cited by 20 publications

References 32 publications

Diagnosing peripheral neuropathy in South‐East Asia: A focus on diabetic neuropathy

Diagnosing peripheral neuropathy in South‐East Asia: A focus on diabetic neuropathy

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy

The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy

Contact Info

Product

Resources

About